Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease
There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti‐oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 si...
Gespeichert in:
| Veröffentlicht in: | Journal of neurochemistry 2003-07, Vol.86 (1), p.267-272 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 272 |
|---|---|
| container_issue | 1 |
| container_start_page | 267 |
| container_title | Journal of neurochemistry |
| container_volume | 86 |
| creator | Klivenyi, Peter Ferrante, Robert J. Gardian, Gabrielle Browne, Susan Chabrier, Pierre‐Etienne Beal, M. Flint |
| description | There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti‐oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti‐oxidants such as BN82451 may be useful for treating HD. |
| doi_str_mv | 10.1046/j.1471-4159.2003.t01-1-01868.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73385292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73385292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4698-a2d34950976e0f6ef97f5367a67f1e9ec43b55ac4968032f8b0ba2bbd33835c23</originalsourceid><addsrcrecordid>eNqVkEtv1DAQgC0EokvhLyBfKKcEv-LEFyS6Atqqai_lbDnOuPIqcYqdLO2_r82u6JmLZ6T5PI8PoTNKakqE_LKrqWhpJWijakYIrxdCK1oR2smufnyFNv_Kr9GGEMYqTgQ7Qe9S2hFCpZD0LTqhrCOtEHKDpstgI5gEA05r3Pu9GbEJAw6wxvkhzgvYxe8Bg3M5S3h2-PymY6Kh2Ads8BJNSPcQvMXTvCbI7wBjwS7WsPhwv8zhc8KDT2XIe_TGmTHBh2M8Rb9-fL_bXlTXtz8vt9-uKyuk6irDBi5UQ1QrgTgJTrWu4bI1snUUFFjB-6YxVijZEc5c15PesL4fOO94Yxk_RWeHvvmC3yukRU8-WRhHEyBvqdsMNkwV8OsBtHFOKYLTD9FPJj5pSnQRrne6GNXFqC7CdRauqf4rXD_mBh-Pk9Z-guHl-9FwBj4dAZOsGV32ZX164YSiRNLCbQ_cHz_C03-uoa9utiXjz17fns0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73385292</pqid></control><display><type>article</type><title>Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease</title><source>Wiley Free Content</source><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Klivenyi, Peter ; Ferrante, Robert J. ; Gardian, Gabrielle ; Browne, Susan ; Chabrier, Pierre‐Etienne ; Beal, M. Flint</creator><creatorcontrib>Klivenyi, Peter ; Ferrante, Robert J. ; Gardian, Gabrielle ; Browne, Susan ; Chabrier, Pierre‐Etienne ; Beal, M. Flint</creatorcontrib><description>There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti‐oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti‐oxidants such as BN82451 may be useful for treating HD.</description><identifier>ISSN: 0022-3042</identifier><identifier>EISSN: 1471-4159</identifier><identifier>DOI: 10.1046/j.1471-4159.2003.t01-1-01868.x</identifier><identifier>PMID: 12807446</identifier><identifier>CODEN: JONRA9</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Administration, Oral ; Animals ; Antioxidants - therapeutic use ; Behavior, Animal - drug effects ; Biological and medical sciences ; Brain - drug effects ; Brain - pathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Disease Models, Animal ; experimental therapeutics ; huntington ; Huntington Disease - drug therapy ; Huntington Disease - genetics ; Huntington Disease - pathology ; Inclusion Bodies - drug effects ; Inclusion Bodies - metabolism ; Inclusion Bodies - pathology ; inflammation ; Medical sciences ; Mice ; Mice, Transgenic ; Motor Activity - drug effects ; neurodegeneration ; Neurology ; Neurons - drug effects ; Neurons - metabolism ; Neurons - pathology ; Neuroprotective Agents - therapeutic use ; oxidative damage ; Survival Rate ; transgenic mice ; Treatment Outcome ; Ubiquitin - biosynthesis</subject><ispartof>Journal of neurochemistry, 2003-07, Vol.86 (1), p.267-272</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4698-a2d34950976e0f6ef97f5367a67f1e9ec43b55ac4968032f8b0ba2bbd33835c23</citedby><cites>FETCH-LOGICAL-c4698-a2d34950976e0f6ef97f5367a67f1e9ec43b55ac4968032f8b0ba2bbd33835c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1471-4159.2003.t01-1-01868.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1471-4159.2003.t01-1-01868.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14910616$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12807446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klivenyi, Peter</creatorcontrib><creatorcontrib>Ferrante, Robert J.</creatorcontrib><creatorcontrib>Gardian, Gabrielle</creatorcontrib><creatorcontrib>Browne, Susan</creatorcontrib><creatorcontrib>Chabrier, Pierre‐Etienne</creatorcontrib><creatorcontrib>Beal, M. Flint</creatorcontrib><title>Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease</title><title>Journal of neurochemistry</title><addtitle>J Neurochem</addtitle><description>There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti‐oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti‐oxidants such as BN82451 may be useful for treating HD.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antioxidants - therapeutic use</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - pathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Disease Models, Animal</subject><subject>experimental therapeutics</subject><subject>huntington</subject><subject>Huntington Disease - drug therapy</subject><subject>Huntington Disease - genetics</subject><subject>Huntington Disease - pathology</subject><subject>Inclusion Bodies - drug effects</subject><subject>Inclusion Bodies - metabolism</subject><subject>Inclusion Bodies - pathology</subject><subject>inflammation</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Motor Activity - drug effects</subject><subject>neurodegeneration</subject><subject>Neurology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neurons - pathology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>oxidative damage</subject><subject>Survival Rate</subject><subject>transgenic mice</subject><subject>Treatment Outcome</subject><subject>Ubiquitin - biosynthesis</subject><issn>0022-3042</issn><issn>1471-4159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkEtv1DAQgC0EokvhLyBfKKcEv-LEFyS6Atqqai_lbDnOuPIqcYqdLO2_r82u6JmLZ6T5PI8PoTNKakqE_LKrqWhpJWijakYIrxdCK1oR2smufnyFNv_Kr9GGEMYqTgQ7Qe9S2hFCpZD0LTqhrCOtEHKDpstgI5gEA05r3Pu9GbEJAw6wxvkhzgvYxe8Bg3M5S3h2-PymY6Kh2Ads8BJNSPcQvMXTvCbI7wBjwS7WsPhwv8zhc8KDT2XIe_TGmTHBh2M8Rb9-fL_bXlTXtz8vt9-uKyuk6irDBi5UQ1QrgTgJTrWu4bI1snUUFFjB-6YxVijZEc5c15PesL4fOO94Yxk_RWeHvvmC3yukRU8-WRhHEyBvqdsMNkwV8OsBtHFOKYLTD9FPJj5pSnQRrne6GNXFqC7CdRauqf4rXD_mBh-Pk9Z-guHl-9FwBj4dAZOsGV32ZX164YSiRNLCbQ_cHz_C03-uoa9utiXjz17fns0</recordid><startdate>200307</startdate><enddate>200307</enddate><creator>Klivenyi, Peter</creator><creator>Ferrante, Robert J.</creator><creator>Gardian, Gabrielle</creator><creator>Browne, Susan</creator><creator>Chabrier, Pierre‐Etienne</creator><creator>Beal, M. Flint</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200307</creationdate><title>Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease</title><author>Klivenyi, Peter ; Ferrante, Robert J. ; Gardian, Gabrielle ; Browne, Susan ; Chabrier, Pierre‐Etienne ; Beal, M. Flint</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4698-a2d34950976e0f6ef97f5367a67f1e9ec43b55ac4968032f8b0ba2bbd33835c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antioxidants - therapeutic use</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - pathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Disease Models, Animal</topic><topic>experimental therapeutics</topic><topic>huntington</topic><topic>Huntington Disease - drug therapy</topic><topic>Huntington Disease - genetics</topic><topic>Huntington Disease - pathology</topic><topic>Inclusion Bodies - drug effects</topic><topic>Inclusion Bodies - metabolism</topic><topic>Inclusion Bodies - pathology</topic><topic>inflammation</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Motor Activity - drug effects</topic><topic>neurodegeneration</topic><topic>Neurology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neurons - pathology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>oxidative damage</topic><topic>Survival Rate</topic><topic>transgenic mice</topic><topic>Treatment Outcome</topic><topic>Ubiquitin - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klivenyi, Peter</creatorcontrib><creatorcontrib>Ferrante, Robert J.</creatorcontrib><creatorcontrib>Gardian, Gabrielle</creatorcontrib><creatorcontrib>Browne, Susan</creatorcontrib><creatorcontrib>Chabrier, Pierre‐Etienne</creatorcontrib><creatorcontrib>Beal, M. Flint</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klivenyi, Peter</au><au>Ferrante, Robert J.</au><au>Gardian, Gabrielle</au><au>Browne, Susan</au><au>Chabrier, Pierre‐Etienne</au><au>Beal, M. Flint</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease</atitle><jtitle>Journal of neurochemistry</jtitle><addtitle>J Neurochem</addtitle><date>2003-07</date><risdate>2003</risdate><volume>86</volume><issue>1</issue><spage>267</spage><epage>272</epage><pages>267-272</pages><issn>0022-3042</issn><eissn>1471-4159</eissn><coden>JONRA9</coden><abstract>There is substantial evidence that excitotoxicity and oxidative damage may contribute to Huntington's disease (HD) pathogenesis. We examined whether the novel anti‐oxidant compound BN82451 exerts neuroprotective effects in the R6/2 transgenic mouse model of HD. Oral administration of BN82451 significantly improved motor performance and improved survival by 15%. Oral administration of BN82451 significantly reduced gross brain atrophy, neuronal atrophy and the number of neuronal intranuclear inclusions at 90 days of age. These findings provide evidence that novel anti‐oxidants such as BN82451 may be useful for treating HD.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12807446</pmid><doi>10.1046/j.1471-4159.2003.t01-1-01868.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3042 |
| ispartof | Journal of neurochemistry, 2003-07, Vol.86 (1), p.267-272 |
| issn | 0022-3042 1471-4159 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73385292 |
| source | Wiley Free Content; MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Administration, Oral Animals Antioxidants - therapeutic use Behavior, Animal - drug effects Biological and medical sciences Brain - drug effects Brain - pathology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Disease Models, Animal experimental therapeutics huntington Huntington Disease - drug therapy Huntington Disease - genetics Huntington Disease - pathology Inclusion Bodies - drug effects Inclusion Bodies - metabolism Inclusion Bodies - pathology inflammation Medical sciences Mice Mice, Transgenic Motor Activity - drug effects neurodegeneration Neurology Neurons - drug effects Neurons - metabolism Neurons - pathology Neuroprotective Agents - therapeutic use oxidative damage Survival Rate transgenic mice Treatment Outcome Ubiquitin - biosynthesis |
| title | Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A34%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20survival%20and%20neuroprotective%20effects%20of%20BN82451%20in%20a%20transgenic%20mouse%20model%20of%20Huntington's%20disease&rft.jtitle=Journal%20of%20neurochemistry&rft.au=Klivenyi,%20Peter&rft.date=2003-07&rft.volume=86&rft.issue=1&rft.spage=267&rft.epage=272&rft.pages=267-272&rft.issn=0022-3042&rft.eissn=1471-4159&rft.coden=JONRA9&rft_id=info:doi/10.1046/j.1471-4159.2003.t01-1-01868.x&rft_dat=%3Cproquest_cross%3E73385292%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73385292&rft_id=info:pmid/12807446&rfr_iscdi=true |